Strategy and business model

Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

This strategy allows Dicot the opportunity to achieve positive cash flow relatively early through payments when agreements are signed and thereafter receive milestone-payments when certain goals have been reached. Furthermore, Dicot expects to be able to obtain royalties on sales. Dicot will have the opportunity to segment the market based on different regions (EU, USA, China, India etc.) and on indications which will be used in order to maximize the outcome.